Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
FibroBiologics, Inc. Common Stock (FBLG)
USD0.84
-0.01 (-1.03%)
US NASDAQ Healthcare Biotechnology
Address
455 East Medical Center Boulevard 77598
Houston, DE, US
Houston, DE, US
CEO
Peter O'Heeron
Website
fibrobiologics.com
IPO
2024-02-01
CIK 1958777 ISIN US31573L2043
Description
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.84
-0.01 (-1.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
262.7K
Beta
1.15
Float Shares
1.60M
Free Float %
76.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.11% | -10.57% | -19.71% | -78.09% | -83.61% | -75.56% | -93.45% | -99.81% | -99.81% | -99.81% | -99.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.84
Low
180.00
+21,257.4%
Consensus
180.00
+21,257.4%
Median
180.00
+21,257.4%
High
180.00
+21,257.4%
DCF (Unlevered)
1.11
+32.0%
DCF (Levered)
1.11
+32.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
180.00
+21,257.4%
|
Quality scores
Altman Z-Score
-23.58
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-23.5% Q1'26: +20.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-502.2% Q1'26: -596.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+35.9% Q1'26: +21.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.14× Q1'26: -0.12× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
7.46M
7.46M – 7.46M
|
10.72M
10.72M – 10.72M
+43.7% YoY
|
62.47M
62.47M – 62.47M
+482.7% YoY
|
| EBITDA |
-10.57M
|
-17.61M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-11.14M
|
-18.44M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-11.16M
est: -11.24M (+0.7%)
|
-18.65M
est: -20.03M (+6.9%)
|
-6.27M
-6.83M – -5.71M
+68.7% YoY
|
-5.43M
-5.48M – -5.37M
+13.4% YoY
|
-6.82M
-12.35M – -1.30M
-25.7% YoY
|
-8.40M
-8.40M – -8.40M
-23.1% YoY
|
-2.09M
-2.09M – -2.09M
+75.1% YoY
|
| SGA |
9.23M
|
9.24M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-6.80
est: -0.34 (-1,888.3%)
|
-8.40
est: -9.07 (+7.4%)
|
-2.81
-3.06 – -2.56
+69.0% YoY
|
-2.43
-2.45 – -2.41
+13.4% YoY
|
-2.77
-5.53 – -0.58
-13.8% YoY
|
-3.76
-3.76 – -3.76
-35.9% YoY
|
-0.94
-0.94 – -0.94
+75.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Maxim Group | Buy | Hold | Downgrade |
| 2026-04-16 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
44
Total invested
993.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
44
-9 vs prev Q
New positions
7
Closed positions
16
Increased
14
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1.22M -17.4K (-1.4%) | 273.7K -400.0K (-59.4%) | 2.82% -0.370 pp | 0.00% +0.000 pp | USD2.34 -90.6% | 7 qtrs — |
| 2 | BLACKROCK, INC. | 482.4K +42.6K (+9.7%) | 108.5K -131.7K (-54.8%) | 1.12% -0.018 pp | 0.00% +0.000 pp | USD2.82 -92.2% | 6 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 348.8K +59.8K (+20.7%) | 78.5K -79.4K (-50.3%) | 0.81% +0.062 pp | 0.00% +0.000 pp | USD3.06 -92.8% | 8 qtrs — |
| 4 | CASCADE FINANCIAL PARTNERS, LLC | 314.6K +16.5K (+5.5%) | 70.7K -92.1K (-56.5%) | 0.73% -0.041 pp | 0.01% -0.012 pp | USD3.39 -93.5% | 7 qtrs — |
| 5 | MILLENNIUM MANAGEMENT LLC | 288.5K -157.7K (-35.3%) | 64.9K -178.8K (-73.4%) | 0.67% -0.485 pp | 0.00% 0.000 pp | USD0.62 -64.5% | 3 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 231.6K +171.8K (+287.3%) | 52.1K +19.4K (+59.5%) | 0.54% +0.383 pp | 0.00% +0.000 pp | USD0.31 -29.0% | 2 qtrs — |
| 7 | JANE STREET GROUP, LLC | 149.8K +149.8K (+100.0%) | 33.7K +33.7K (+100.0%) | 0.35% +0.348 pp | 0.00% +0.000 pp | USD0.22 +0.0% | 6 qtrs — |
| 8 | AMG NATIONAL TRUST BANK | 139.0K +139.0K (+100.0%) | 31.3K +31.3K (+100.0%) | 0.32% +0.323 pp | 0.00% +0.001 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 9 | UBS GROUP AG | 120.8K +43.3K (+56.0%) | 27.2K -15.1K (-35.7%) | 0.28% +0.080 pp | 0.00% +0.000 pp | USD1.80 -87.8% | 8 qtrs — |
| 10 | STATE STREET CORP | 111.3K +— (+0.0%) | 25.0K -35.8K (-58.8%) | 0.26% -0.030 pp | 0.00% +0.000 pp | USD3.50 -93.7% | 7 qtrs — |
| 11 | OPTIVISE ADVISORY SERVICES LLC | 110.1K +— (+0.0%) | 24.8K -35.4K (-58.8%) | 0.26% -0.029 pp | 0.01% -0.022 pp | USD4.00 -94.5% | 7 qtrs — |
| 12 | REQUISITE CAPITAL MANAGEMENT, LLC | 109.7K +— (+0.0%) | 24.7K -35.3K (-58.8%) | 0.25% -0.029 pp | 0.00% -0.005 pp | USD4.00 -94.5% | 7 qtrs — |
| 13 | WILEY BROS.-AINTREE CAPITAL, LLC | 100.0K +— (+0.0%) | 22.5K -32.1K (-58.8%) | 0.23% -0.027 pp | 0.00% 0.000 pp | USD0.60 -63.3% | 3 qtrs — |
| 14 | CERITY PARTNERS LLC | 93.9K -32.0K (-25.4%) | 21.1K -47.7K (-69.3%) | 0.22% -0.108 pp | 0.00% 0.000 pp | USD1.94 -88.7% | 6 qtrs — |
| 15 | AMERICAN INSTITUTE FOR ADVANCED INVESTMENT MANAGEMENT, LLP | 88.2K +— (+0.0%) | 19.8K -28.3K (-58.8%) | 0.20% -0.024 pp | 0.01% -0.019 pp | USD4.00 -94.5% | 7 qtrs — |
| 16 | SAXON INTERESTS, INC. | 57.0K +57.0K (+100.0%) | 12.8K +12.8K (+100.0%) | 0.13% +0.132 pp | 0.00% +0.005 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 17 | BANK OF AMERICA CORP /DE/ | 48.2K +1.0 (+0.0%) | 10.8K -15.5K (-59.0%) | 0.11% -0.013 pp | 0.00% +0.000 pp | USD3.74 -94.1% | 7 qtrs — |
| 18 | NORTHERN TRUST CORP | 47.7K +— (+0.0%) | 10.7K -15.3K (-58.8%) | 0.11% -0.013 pp | 0.00% +0.000 pp | USD3.06 -92.8% | 6 qtrs — |
| 19 | RMR WEALTH BUILDERS | 38.4K +— (+0.0%) | 8.6K -12.3K (-58.8%) | 0.09% -0.010 pp | 0.00% -0.001 pp | USD3.97 -94.5% | 7 qtrs — |
| 20 | XTX TOPCO LTD | 37.9K +37.9K (+100.0%) | 8.5K +8.5K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.000 pp | USD0.22 +0.0% | 4 qtrs — |
| 21 | CONCURRENT INVESTMENT ADVISORS, LLC | 35.3K +— (+0.0%) | 7.9K -11.3K (-58.8%) | 0.08% -0.009 pp | 0.00% 0.000 pp | USD4.00 -94.5% | 7 qtrs — |
| 22 | DRW SECURITIES, LLC | 33.3K +33.3K (+100.0%) | 7.5K +7.5K (+100.0%) | 0.08% +0.077 pp | 0.00% +0.000 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 23 | ETHOS FINANCIAL GROUP, LLC | 24.4K +— (+0.0%) | 5.5K -7.8K (-58.8%) | 0.06% -0.007 pp | 0.00% -0.001 pp | USD2.31 -90.5% | 7 qtrs — |
| 24 | RAYMOND JAMES FINANCIAL INC | 18.6K +— (+0.0%) | 4.2K -6.0K (-58.8%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD2.00 -89.0% | 5 qtrs — |
| 25 | TOWER RESEARCH CAPITAL LLC (TRC) | 18.1K +1.1K (+6.8%) | 4.1K -5.2K (-56.0%) | 0.04% -0.002 pp | 0.00% 0.000 pp | USD1.27 -82.7% | 6 qtrs — |
| 26 | CETERA INVESTMENT ADVISERS | 18.0K +— (+0.0%) | 4.1K -5.8K (-58.8%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD2.38 -90.8% | 6 qtrs — |
| 27 | NEWEDGE ADVISORS, LLC | 16.9K +— (+0.0%) | 3.8K -5.4K (-58.8%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD9.02 -97.6% | 8 qtrs — |
| 28 | QUBE RESEARCH & TECHNOLOGIES LTD | 16.8K -13.1K (-43.8%) | 3.8K -12.6K (-76.9%) | 0.04% -0.039 pp | 0.00% +0.000 pp | USD0.62 -64.5% | 3 qtrs — |
| 29 | CAHABA WEALTH MANAGEMENT, INC. | 14.7K +— (+0.0%) | 3.3K -4.7K (-58.8%) | 0.03% -0.004 pp | 0.00% 0.000 pp | USD4.00 -94.5% | 7 qtrs — |
| 30 | FLAHARTY ASSET MANAGEMENT, LLC | 14.7K +— (+0.0%) | 3.3K -4.7K (-58.8%) | 0.03% -0.004 pp | 0.00% -0.001 pp | USD3.09 -92.9% | 6 qtrs — |
| 31 | POINT72 ASSET MANAGEMENT, L.P. | 14.5K +14.5K (+100.0%) | 3.3K +3.3K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 32 | SKOPOS LABS, INC. | 11.5K +— (+0.0%) | 2.9K -4.2K (-59.6%) | 0.03% -0.003 pp | 0.00% -0.001 pp | USD2.00 -89.0% | 5 qtrs — |
| 33 | GOLDMAN SACHS GROUP INC | 10.5K +— (+0.0%) | 2.4K -3.4K (-58.8%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD1.74 -87.4% | 7 qtrs — |
| 34 | GLOBAL ASSETS ADVISORY, LLC | 10.5K -250.0 (-2.3%) | 2.4K -3.5K (-59.8%) | 0.02% -0.003 pp | 0.00% -0.001 pp | USD0.55 -60.0% | 2 qtrs — |
| 35 | CWA ASSET MANAGEMENT GROUP, LLC | 10.0K +— (+0.0%) | 2.2K -3.2K (-58.8%) | 0.02% -0.003 pp | 0.00% 0.000 pp | USD0.55 -60.0% | 2 qtrs — |
| 36 | ADVISOR GROUP HOLDINGS, INC. | 6.0K -2.0K (-25.0%) | 1.3K -3.5K (-72.6%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD2.94 -92.5% | 7 qtrs — |
| 37 | ISLAY CAPITAL MANAGEMENT, LLC | 3.4K +— (+0.0%) | 763.00 -1.1K (-58.8%) | 0.01% -0.001 pp | 0.00% -0.001 pp | USD0.56 -60.7% | 3 qtrs — |
| 38 | GROVE BANK & TRUST | 2.0K +— (+0.0%) | 450.00 -642.0 (-58.8%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD2.45 -91.0% | 7 qtrs — |
| 39 | DISCIPLINED EQUITY MANAGEMENT, INC. | 1.0K +1.0K (+100.0%) | 418.00 +418.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD0.22 +0.0% | 1 qtrs NEW |
| 40 | BNP PARIBAS ARBITRAGE, SNC | 1.3K +— (+0.0%) | 294.00 -419.0 (-58.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.39 -93.5% | 7 qtrs — |
| 41 | ALLWORTH FINANCIAL LP | 261.00 +— (+0.0%) | 59.00 -84.0 (-58.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD11.41 -98.1% | 8 qtrs — |
| 42 | WELLS FARGO & COMPANY/MN | 200.00 +— (+0.0%) | 45.00 -64.0 (-58.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.38 -93.5% | 8 qtrs — |
| 43 | OPTIVER HOLDING B.V. | 26.00 +— (+0.0%) | 6.00 -8.0 (-57.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.54 -59.3% | 2 qtrs — |
| 44 | DEUTSCHE BANK AG\ | 18.00 +— (+0.0%) | 4.00 -6.0 (-60.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.06 -89.3% | 7 qtrs — |
| 45 | YORKVILLE ADVISORS GLOBAL, LP | — -509.8K (-100.0%) | — -278.4K (-100.0%) | 0.00% -1.320 pp | 0.00% -0.108 pp | USD— | 3 qtrs SOLD |
| 46 | GTS SECURITIES LLC | — -308.7K (-100.0%) | — -168.5K (-100.0%) | 0.00% -0.799 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 47 | HRT FINANCIAL LP | — -44.1K (-100.0%) | — -24.0K (-100.0%) | 0.00% -0.114 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 48 | IFP ADVISORS, INC | — -2.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 49 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | — -350.0K (-100.0%) | — -191.2K (-100.0%) | 0.00% -0.906 pp | 0.00% -0.012 pp | USD— | 2 qtrs SOLD |
| 50 | LPL FINANCIAL LLC | — -17.6K (-100.0%) | — -9.6K (-100.0%) | 0.00% -0.046 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 51 | LUMINUS MANAGEMENT LLC | — -26.6K (-100.0%) | — -345.8K (-100.0%) | 0.00% -0.069 pp | 0.00% -0.311 pp | USD— | 2 qtrs SOLD |
| 52 | MORGAN STANLEY | — -13.0 (-100.0%) | — -7.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 53 | FMR LLC | — -1.2K (-100.0%) | — -655.0 (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 54 | EVERSOURCE WEALTH ADVISORS, LLC | — -52.0 (-100.0%) | — -28.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 55 | ROYAL BANK OF CANADA | — -2.0K (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 56 | RUNNYMEDE CAPITAL ADVISORS, INC. | — -10.0K (-100.0%) | — -5.5K (-100.0%) | 0.00% -0.026 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 57 | CITADEL ADVISORS LLC | — -211.1K (-100.0%) | — -115.3K (-100.0%) | 0.00% -0.547 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 58 | SRS CAPITAL ADVISORS, INC. | — -2.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 59 | TRUE WEALTH DESIGN, LLC | — -10.0 (-100.0%) | — -6.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 60 | BARCLAYS PLC | — -40.0K (-100.0%) | — -123.5K (-100.0%) | 0.00% -0.103 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 31.5K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 98.11 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 269.37 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 19.90 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 46.0K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 100.66 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 54.91 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 22.00 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 2.43 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.35 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
191.5K
Shares disposed
—
Cash buys
6.00
Cash sales
—
Net activity
+191,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | O'HEERON PETE | Director / Officer | P-Purchase | A | Common Stock | 15,872 | 0.38 | 6.0K | 5,958,147 | D | ↗ |
| 2026-03-04 | Khoja Hamid | Officer | P-Purchase | A | Common Stock | 30,000 | 0.38 | 11.4K | 61,250 | D | ↗ |
| 2026-03-03 | O'HEERON PETE | Director / Officer | P-Purchase | A | Common Stock | 18,200 | 0.41 | 7.4K | 5,942,275 | D | ↗ |
| 2026-03-02 | O'HEERON PETE | Director / Officer | P-Purchase | A | Common Stock | 17,428 | 0.35 | 6.2K | 5,924,075 | D | ↗ |
| 2026-03-02 | Davis Jason | Officer | P-Purchase | A | Common Stock | 70,000 | 0.41 | 29.0K | 70,000 | D | ↗ |
| 2026-02-27 | GARCIA RUBEN A | Officer | P-Purchase | A | Common Stock | 40,000 | 0.33 | 13.1K | 180,000 | D | ↗ |
| 2025-12-11 | GARCIA RUBEN A | Officer | P-Purchase | A | Common Stock | 140,000 | 0.34 | 47.6K | 140,000 | D | ↗ |
| 2025-06-12 | Niklas Victoria Ninon Olivia | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.87 | 19.2K | 22,000 | D | ↗ |
| 2025-06-12 | Link Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.87 | 19.2K | 22,000 | D | ↗ |
| 2025-06-12 | Hoffman Robert E. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.87 | 19.2K | 22,000 | D | ↗ |
| 2025-06-12 | Coen Stacy Ann | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.87 | 19.2K | 22,000 | D | ↗ |
| 2025-06-12 | Cilento Richard C. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.87 | 19.2K | 22,000 | D | ↗ |
| 2025-06-09 | Davis Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 0.94 | 425.2K | 450,000 | D | ↗ |
| 2025-05-27 | Khoja Hamid | Officer | P-Purchase | A | Common Stock | 20,000 | 0.84 | 16.8K | 31,250 | D | ↗ |
| 2025-03-26 | O'HEERON PETE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 453,000 | 1.04 | 471.1K | 453,000 | D | ↗ |
| 2025-03-26 | Khoja Hamid | Officer | A-Award | A | Stock Option (Right to Buy) | 189,000 | 1.04 | 196.6K | 189,000 | D | ↗ |
| 2025-03-26 | GARCIA RUBEN A | Officer | A-Award | A | Stock Option (Right to Buy) | 189,000 | 1.04 | 196.6K | 189,000 | D | ↗ |
| 2024-12-27 | O'HEERON PETE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 406,339 | 2.36 | 959.0K | 406,339 | D | ↗ |
| 2024-12-27 | Khoja Hamid | Officer | A-Award | A | Stock Option (Right to Buy) | 176,200 | 2.36 | 415.8K | 176,200 | D | ↗ |
| 2024-12-27 | GARCIA RUBEN A | Officer | A-Award | A | Stock Option (Right to Buy) | 176,200 | 2.36 | 415.8K | 176,200 | D | ↗ |
| 2024-12-09 | O'HEERON PETE | Director / Officer | G-Gift | D | Common Stock | 100,000 | 0.00 | — | 5,906,647 | D | ↗ |
| 2024-12-03 | O'HEERON PETE | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 6,006,647 | D | ↗ |
Executive team
Top executives
Shares Outstanding
2.10M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Ruben A. Garcia General Counsel | 270.8K | 15.0K | — | 2.28M | 142.2K | 41.5K | 2.75M | 82.94% | ↗ |
| 2 | 2024 | Pete O’Heeron Chairperson and CEO | 600.0K | — | — | 788.5K | 390.0K | 26.7K | 1.81M | 43.68% | ↗ |
| 3 | 2024 | Hamid Khoja, Ph.D. Chief Scientific Officer | 325.0K | — | — | 341.9K | 150.0K | 36.8K | 853.6K | 40.05% | ↗ |
| 4 | 2023 | Pete O’Heeron Chairperson and CEO | 600.0K | — | — | 3.34M | 300.0K | 50.9K | 4.29M | 77.82% | ↗ |
| 5 | 2023 | Hamid Khoja, Ph.D. Chief Scientific Officer | 325.0K | — | — | 818.1K | 113.8K | 50.9K | 1.31M | 62.56% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter O'Heeron | Founder, Chairperson & Chief Executive Officer | 657.4K | male |
| Jason D. Davis | Chief Financial Officer | 509.3K | male |
| Hamid Khoja | Chief Scientific Officer | 483.5K | — |
| Ruben A. Garcia | General Counsel | 456.2K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FBLG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
